Numerous missteps have weighed on C3.ai, while Palantir Technologies has excelled. The company's new CEO will need time to steer the ship in the right direction. Consistently positive free cash flow ...
C3.ai, Inc. (NASDAQ: AI) stock is trending ahead of the company’s second-quarter earnings report, which is expected after the market closes. What To Know: Analysts estimate that C3.ai will report an ...
In a highly anticipated article, FDA officials Vinay Prasad, M.D., and Martin Makary, M.D., outlined a novel regulatory pathway that could trigger a seismic shift in how bespoke gene editing therapies ...
Built by first responders for first responders - complete training and earn certificate in less than an hour OVIEDO, Fla., Nov. 12, 2025 /PRNewswire/ -- Addressing the critical need for nationwide ...
Leadership change follows Siebel stepping down due to health concerns C3 AI's stock down over 54% in 2025 amid financial struggles Ehikian's CEO appointment led to withdrawal of full-year financial ...
Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...
For three days inside the Charleston Convention Center, fire, EMS, law enforcement and dispatchers from the tri-county gathered for training to learn how to better work together during a crisis. The ...
Iptacopan targets one of the major proteins involved in the enzymes of the alternative pathway of complement, explains Carla Nester, MD, of Stead Family Children's Hospital. In April, in part 1 of ...
TSP-1 reduced C3 and C5 cleavage and formation of the membrane attack complex, attenuating complement-mediated injury in AAV models. Complement activation is a relevant driver in the pathomechanisms ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback